

=> d que 152

L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON 223673-61-8/RN
 L7 1 SEA FILE=REGISTRY ABB=ON PLU=ON 223673-61-8/CRN
 L8 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L6
 L9 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L7
 L10 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 OR L9
 L11 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L6/DP OR L6/D
 L12 0 SEA FILE=HCAPLUS ABB=ON PLU=ON L7/DP OR L7/D
 L13 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 OR L11 OR L12
 L14 207 SEA FILE=HCAPLUS ABB=ON PLU=ON TAKASU, T?/AU
 L15 14520 SEA FILE=HCAPLUS ABB=ON PLU=ON SATO, S?/AU
 L16 420 SEA FILE=HCAPLUS ABB=ON PLU=ON UKAI, M?/AU
 L17 5023 SEA FILE=HCAPLUS ABB=ON PLU=ON MARUYAMA, T?/AU
 L18 2694 SEA FILE=HCAPLUS ABB=ON PLU=ON YAMANOUCI PHARMACEUTICAL?
 /CS, PA, SO
 L19 3 SEA FILE=HCAPLUS ABB=ON PLU=ON (L14 OR L15 OR L16 OR L17
 OR L18) AND L13
 L20 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 NOT L19
 L46 1 SEA FILE=REGISTRY ABB=ON PLU=ON 223673-61-8/CRN
 L47 1 SEA FILE=REGISTRY ABB=ON PLU=ON 223673-61-8/RN
 L48 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L46
 L49 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L47
 L50 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L48 OR L49
 L51 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L50 NOT L19
 L52 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L51 OR L20

=> d 151 ibib ed abs hitstr hitind

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L51 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:359077 HCAPLUS Full-text
 DOCUMENT NUMBER: 144:404419
 TITLE: Pharmaceutical composition using a
 β 3-adrenoceptor agonist for treatment of
 complaints connected with disease changes or
 irritations of the prostate
 INVENTOR(S): Michel, Martin Christian
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.,
 Germany
 SOURCE: Ger. Offen., 14 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004050952	A1	20060420	DE 2004-102004050952	20041018
WO 2006042679	A1	20060427	WO 2005-EP10975	20051012

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
 MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ,

10/534,290

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006084700 A1 20060420 US 2005-252838 20051018
PRIORITY APPLN. INFO.: DE 2004-102004050952A 20041018

US 2004-624590P P 20041103

ED Entered STN: 20 Apr 2006

AB The invention describes the use of β 3-adrenoceptor agonists for treatment of complaints connected with the prostate. Among complaints, as they arise with prostatitis, they revert back to inflammatory processes or chronic irritations or complaints as they accompany a benign change of the prostate. The invention is especially suitable for the treatment of benign prostatic hyperplasia.


IT 223673-61-8

(β 3-adrenoceptor agonist for treatment of complaints connected with disease changes or irritations of the prostate)

RN 223673-61-8 HCAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CC 1-12 (Pharmacology)

Section cross-reference(s): 63

IT 122-59-8D, Phenoxyacetic acid, derivs. 95840-76-9 138908-40-4
152357-12-5 159182-43-1 173901-95-6 190063-31-1 193760-08-6
207922-70-1 211030-99-8 220129-58-8 220129-58-8D, metabolites
and enantiomers 221659-13-8 223673-61-8 255733-70-1
255733-73-4 255733-81-4 255733-94-9 255733-96-1 255734-04-4
255734-15-7 268728-18-3 303967-96-6 349636-69-7 373359-67-2
392630-57-8 392644-11-0 445307-55-1 445307-58-4 481702-56-1
883724-07-0 883724-08-1 883724-09-2 883724-10-5 883724-11-6

(β 3-adrenoceptor agonist for treatment of complaints connected with disease changes or irritations of the prostate)


REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

=> d que 143


L41

STR

PRO



Page 1-A



Page 1-B

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

L43 0 SEA FILE=CASREACT SSS FUL L41 (0 REACTIONS)

=> d que 119

L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON 223673-61-8/RN
 L7 1 SEA FILE=REGISTRY ABB=ON PLU=ON 223673-61-8/CRN
 L8 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L6
 L9 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L7
 L10 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L8 OR L9
 L11 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L6/DP OR L6/D
 L12 0 SEA FILE=HCAPLUS ABB=ON PLU=ON L7/DP OR L7/D
 L13 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 OR L11 OR L12
 L14 207 SEA FILE=HCAPLUS ABB=ON PLU=ON TAKASU, T?/AU
 L15 14520 SEA FILE=HCAPLUS ABB=ON PLU=ON SATO, S?/AU
 L16 420 SEA FILE=HCAPLUS ABB=ON PLU=ON UKAI, M?/AU
 L17 5023 SEA FILE=HCAPLUS ABB=ON PLU=ON MARUYAMA, T?/AU
 L18 2694 SEA FILE=HCAPLUS ABB=ON PLU=ON YAMANOUCHI PHARMACEUTICAL?
 /CS, PA, SO
 L19 3 SEA FILE=HCAPLUS ABB=ON PLU=ON (L14 OR L15 OR L16 OR L17
 OR L18) AND L13

=> d 119 1-3 ibib ed abs hitstr hitind

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:412811 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:400085
 TITLE: Remedy for overactive bladder comprising acetic
 acid anilide derivative as the active ingredient
 INVENTOR(S): **Takasu, Toshiyuki; Sato, Shuichi**
 ; **Ukai, Masashi; Maruyama,**
Tatsuya
 PATENT ASSIGNEE(S): **Yamanouchi Pharmaceutical Co.,**
 Ltd., Japan
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041276	A1	20040521	WO 2003-JP14065	20031104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2503570	A1	20040521	CA 2003-2503570	20031104
AU 2003284700	A1	20040607	AU 2003-284700	20031104

EP 1559427 A1 20050803 EP 2003-770134 20031104
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
 PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003016080 A 20050927 BR 2003-16080 20031104
 CN 1711085 A 20051221 CN 2003-80102889 20031104
 JP 3815496 B2 20060830 JP 2004-549600 20031104
 US 2006115540 A1 20060601 US 2005-534290 20050509
 NO 2005002691 A 20050715 NO 2005-2691 20050606
 PRIORITY APPLN. INFO.: JP 2002-323792 A 20021107

WO 2003-JP14065 W 20031104

ED Entered STN: 21 May 2004

AB (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination function measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for overactive bladder.


IT 223673-61-8DP, salts 223673-61-8P

(remedy for overactive bladder comprising (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide derivative as the active ingredient)

RN 223673-61-8 HCAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[[2-(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-61-8 HCAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[[2-(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-426
 ICS A61P013-10; A61P013-00; C07D277-40
 CC 1-10 (Pharmacology)
 Section cross-reference(s): 28, 63
 IT **223673-61-8DP**, salts **223673-61-8P**
 (remedy for overactive bladder comprising (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide derivative as the active ingredient)

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:356433 HCAPLUS Full-text

DOCUMENT NUMBER: 138:368881

TITLE: Process for preparation of α -form and β -form crystals of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide for treatment of diabetes

INVENTOR(S): Kawazoe, Souichirou; Sakamoto, Kenichirou;
 Awamura, Yuji; **Maruyama, Tatsuya**;
 Suzuki, Takayuki; Onda, Kenichi; **Takasu, Toshiyuki**

PATENT ASSIGNEE(S): **Yamanouchi Pharmaceutical Co., Ltd.**, Japan

SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037881	A1	20030508	WO 2002-JP11217	20021029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2464068	A1	20030508	CA 2002-2464068	20021029
EP 1440969	A1	20040728	EP 2002-779929	20021029
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013570	A	20041026	BR 2002-13570	20021029
HU 200401665	A2	20041129	HU 2004-1665	20021029
CN 1575287	A	20050202	CN 2002-821370	20021029
JP 3800220	B2	20060726	JP 2003-540162	20021029
ZA 2004003044	A	20050421	ZA 2004-3044	20040421
IN 2004KN00553	A	20070126	IN 2004-KN553	20040427
US 2005004190	A1	20050106	US 2004-494018	20040429
NO 2004002227	A	20040528	NO 2004-2227	20040528
PRIORITY APPLN. INFO.:			JP 2001-332914	A 20011030
			WO 2002-JP11217	W 20021029

ED Entered STN: 09 May 2003

AB This invention pertains to prepn method for α -form and β -form crystals of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide, which are useful as starting materials for a diabetes remedy. The α -form crystal has no hygroscopicity, has stability which makes the crystal usable in a medicine, and is useful for mass synthesis in industrial production. The β -form crystal has relatively low hygroscopicity and is useful also as an intermediate for the α -form crystal. For example, the title compound was prepared in a four-step synthesis comprising coupling reactions in good yield. The α -form and β -form crystals of the title compound were prepared by recrystn. The title compound reduced blood sugar in rat with ED30 of <3.5 mg/kg/day.


IT 223673-61-8P

(intermediate; preparation of (aminothiazolyl)acetanilide derivs. via coupling reactions for treatment of diabetes)

RN 223673-61-8 HCAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 223672-18-2P

(preparation of (aminothiazolyl)acetanilide derivs. via coupling reactions for treatment of diabetes)

RN 223672-18-2 HCAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IC ICM C07D277-40

ICS A61K031-426; A61P003-10



CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 45
 IT 223673-61-8P 521284-19-5P 521284-21-9P 521284-22-0P
 (intermediate; preparation of (aminothiazolyl)acetanilide derivs. via
 coupling reactions for treatment of diabetes)
 IT 223672-18-2P
 (preparation of (aminothiazolyl)acetanilide derivs. via coupling
 reactions for treatment of diabetes)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:282201 HCAPLUS Full-text
 DOCUMENT NUMBER: 130:311793
 TITLE: Preparation of amides as antidiabetics
 INVENTOR(S): **Maruyama, Tatsuya**; Suzuki, Takayuki;
 Onda, Kenichi; Hayakawa, Masahiko; Moritomo,
 Hiroyuki; Kimizuka, Tetsuya; Matsui, Tetsuo
 PATENT ASSIGNEE(S): **Yamanouchi Pharmaceutical Co.,**
 Ltd., Japan
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920607	A1	19990429	WO 1998-JP4671	19981015
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9889288	A	19990506	AU 1998-89288	19981013
AU 736676	B2	20010802		
CA 2305802	A1	19990429	CA 1998-2305802	19981015
AU 9894621	A	19990510	AU 1998-94621	19981015
BR 9804500	A	20000411	BR 1998-4500	19981015
EP 1028111	A1	20000816	EP 1998-947894	19981015
EP 1028111	B1	20040512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 3193706	B2	20010730	JP 2000-516949	19981015
TW 557295	B	20031011	TW 1998-87117145	19981015
AT 266639	T	20040515	AT 1998-947894	19981015
PT 1028111	T	20040930	PT 1998-947894	19981015
ES 2221204	T3	20041216	ES 1998-947894	19981015
CN 1218045	A	19990602	CN 1998-121375	19981016
CN 1136192	B	20040128		
HU 9802417	A2	19990830	HU 1998-2417	19981016
RU 2186763	C2	20020810	RU 1998-118906	19981016
US 6346532	B1	20020212	US 2000-529096	20000407
NO 2000001983	A	20000414	NO 2000-1983	20000414
NO 316673	B1	20040329		
PRIORITY APPLN. INFO.:			JP 1997-285778	A 19971017

OTHER SOURCE(S): MARPAT 130:311793
 ED Entered STN: 07 May 1999
 GI



AB The title compds. I [ring B = an optionally substituted heteroaryl optionally fused with a benzene ring; X = a bond, lower alkylene or lower alkenylene (optionally substituted by hydroxy or lower alkyl), carbonyl, or NH (further details related to X are given); A = a lower alkylene or a group represented by (lower alkylene)-O; R1a and R1b = hydrogen or lower alkyl; R2 = hydrogen or halogeno; and Z = nitrogen or CH] are prepared I are useful as diabetes remedies which not only function to accelerate the secretion of insulin and enhance insulin sensitivity but also have an anti-obesity action and an antihyperlipemic action based on their selective stimulative action on β_3 receptor. For example, imidazole derivative II was prepared Compds. of this invention significantly decreased blood sugar in mice.


IT 223672-18-2P 223673-61-8P

(preparation of amides as antidiabetics)

RN 223672-18-2 HCAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-61-8 HCAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM C07D213-56

ICS C07D213-61; C07D213-64; C07D213-73; C07D213-81; C07D215-12;
C07D215-48; C07D217-22; C07D231-12; C07D233-64; C07D241-20;
C07D257-04; C07D277-40; C07D277-68; C07D285-08; C07D513-04;
A61K031-41; A61K031-415; A61K031-425; A61K031-44CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 27

IT	223672-09-1P	223672-10-4P	223672-11-5P	223672-12-6P
	223672-13-7P	223672-14-8P	223672-15-9P	223672-16-0P
	223672-17-1P	223672-18-2P	223672-19-3P	223672-20-6P
	223672-21-7P	223672-22-8P	223672-23-9P	223672-24-0P
	223672-25-1P	223672-26-2P	223672-27-3P	223672-29-5P
	223672-30-8P	223672-31-9P	223672-32-0P	223672-34-2P
	223672-36-4P	223672-38-6P	223672-40-0P	223672-42-2P
	223672-44-4P	223672-46-6P	223672-47-7P	223672-48-8P
	223672-49-9P	223672-50-2P	223672-51-3P	223672-52-4P
	223672-53-5P	223672-55-7P	223672-58-0P	223672-60-4P
	223672-63-7P	223672-65-9P	223672-66-0P	223672-67-1P
	223672-68-2P	223672-69-3P	223672-70-6P	223672-71-7P
	223672-72-8P	223672-73-9P	223672-74-0P	223672-75-1P
	223672-76-2P	223672-77-3P	223672-78-4P	223672-79-5P
	223672-80-8P	223672-81-9P	223672-82-0P	223672-83-1P
	223672-84-2P	223672-85-3P	223672-86-4P	223672-87-5P
	223672-88-6P	223672-89-7P	223672-90-0P	223672-91-1P
	223672-92-2P	223672-93-3P	223672-94-4P	223672-95-5P
	223672-96-6P	223672-97-7P	223672-98-8P	223672-99-9P
	223673-00-5P	223673-01-6P	223673-02-7P	223673-03-8P
	223673-04-9P	223673-05-0P	223673-06-1P	223673-07-2P

10/534,290

223673-08-3P	223673-09-4P	223673-10-7P	223673-11-8P
223673-12-9P	223673-13-0P	223673-14-1P	223673-15-2P
223673-16-3P	223673-17-4P	223673-18-5P	223673-19-6P
223673-20-9P	223673-21-0P	223673-22-1P	223673-23-2P
223673-25-4P	223673-26-5P	223673-27-6P	223673-28-7P
223673-29-8P	223673-30-1P	223673-31-2P	223673-32-3P
223673-33-4P	223673-58-3P	223673-59-4P	223673-60-7P
223673-61-8P	223673-62-9P	223673-63-0P	223673-64-1P
223673-65-2P	223673-66-3P		

(preparation of amides as antidiabetics)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

=> d his nofile

(FILE 'HOME' ENTERED AT 14:40:16 ON 09 APR 2007)

FILE 'HCAPLUS' ENTERED AT 14:40:25 ON 09 APR 2007

L1 1 SEA ABB=ON PLU=ON US20060115540/PN
SEL RN

FILE 'REGISTRY' ENTERED AT 14:40:43 ON 09 APR 2007

L2 9 SEA ABB=ON PLU=ON (223673-61-8/BI OR 29676-71-9/BI OR
29968-78-3/BI OR 50-18-0/BI OR 521284-19-5/BI OR 521284-20-
8/BI OR 521284-21-9/BI OR 521284-22-0/BI OR 611-71-2/BI)
L3 0 SEA ABB=ON PLU=ON L2 AND AMINOTHIO?
L4 1 SEA ABB=ON PLU=ON L2 AND AMINOTHIA?
L5 1 SEA ABB=ON PLU=ON L2 AND 4-THIAZOLEACETAMIDE
L6 1 SEA ABB=ON PLU=ON 223673-61-8/RN
L7 1 SEA ABB=ON PLU=ON 223673-61-8/CRN

FILE 'HCAPLUS' ENTERED AT 15:05:22 ON 09 APR 2007

L8 4 SEA ABB=ON PLU=ON L6
L9 2 SEA ABB=ON PLU=ON L7
L10 4 SEA ABB=ON PLU=ON L8 OR L9
L11 1 SEA ABB=ON PLU=ON L6/DP OR L6/D
L12 0 SEA ABB=ON PLU=ON L7/DP OR L7/D
L13 4 SEA ABB=ON PLU=ON L10 OR L11 OR L12
L14 207 SEA ABB=ON PLU=ON TAKASU, T?/AU
L15 14520 SEA ABB=ON PLU=ON SATO, S?/AU
L16 420 SEA ABB=ON PLU=ON UKAI, M?/AU
L17 5023 SEA ABB=ON PLU=ON MARUYAMA, T?/AU
L18 2694 SEA ABB=ON PLU=ON YAMANOUCHI PHARMACEUTICAL?/CS,PA,SO
L19 3 SEA ABB=ON PLU=ON (L14 OR L15 OR L16 OR L17 OR L18) AND
L13
L20 1 SEA ABB=ON PLU=ON L13 NOT L19

FILE 'REGISTRY' ENTERED AT 15:09:19 ON 09 APR 2007

E C21 H24 N4 O2 S/MF
L21 1363 SEA ABB=ON PLU=ON "C21 H24 N4 O2 S"/MF
L22 138 SEA ABB=ON PLU=ON L21 AND THIAZO?
L23 61 SEA ABB=ON PLU=ON L22 AND 3/NR
L24 1 SEA ABB=ON PLU=ON L23 AND HYDROXY?
L25 1 SEA ABB=ON PLU=ON 29676-71-9/RN
L26 1 SEA ABB=ON PLU=ON 29968-78-3/RN
L27 1 SEA ABB=ON PLU=ON 521284-19-5/RN
L28 1 SEA ABB=ON PLU=ON 521284-20-8/RN
L29 1 SEA ABB=ON PLU=ON 521284-21-9/RN
L30 1 SEA ABB=ON PLU=ON 521284-22-0/RN
L31 5 SEA ABB=ON PLU=ON (L26 OR L27 OR L28 OR L29 OR L30)

FILE 'HCAPLUS' ENTERED AT 15:14:24 ON 09 APR 2007

L32 83 SEA ABB=ON PLU=ON L25
L33 114 SEA ABB=ON PLU=ON L31
L34 2 SEA ABB=ON PLU=ON L32 AND L33

FILE 'REGISTRY' ENTERED AT 15:14:56 ON 09 APR 2007

L35 0 SEA ABB=ON PLU=ON L6 AND MEDLINE/LC
L36 0 SEA ABB=ON PLU=ON L6 AND BIOSIS/LC
L37 0 SEA ABB=ON PLU=ON L6 AND DRUGU/LC
L38 0 SEA ABB=ON PLU=ON L6 AND EMBASE/LC

FILE 'CASREACT' ENTERED AT 15:16:16 ON 09 APR 2007

L39 STR 223673-61-8
 L40 0 SEA SSS SAM L39 (0 REACTIONS)
 L41 STR L39
 L42 0 SEA SSS SAM L41 (0 REACTIONS)
 L43 0 SEA SSS FUL L41 (0 REACTIONS)

FILE 'REGISTRY' ENTERED AT 15:20:04 ON 09 APR 2007

E C21 H24 N4 O2 S/MF
 L44 52 SEA ABB=ON PLU=ON ("C21 H24 N4 O2 S . 1/2 C2 H6 O6
 S2"/MF OR "C21 H24 N4 O2 S . 2 CL H"/MF OR "C21 H24 N4 O2
 S . 3 CL H"/MF OR "C21 H24 N4 O2 S . BR H"/MF OR "C21 H24
 N4 O2 S . C H4 O3 S"/MF OR "C21 H24 N4 O2 S . C2 H F3
 O2"/MF OR "C21 H24 N4 O2 S . C2 H4 O2"/MF OR "C21 H24 N4
 O2 S . C21 H24 N4 O2 S"/MF OR "C21 H24 N4 O2 S . C4 H4
 O4"/MF OR "C21 H24 N4 O2 S . C7 H8 O3 S"/MF OR "C21 H24 N4
 O2 S . CL H"/MF OR "C21 H24 N4 O2 S . H2 O4 S"/MF OR "C21
 H24 N4 O2 S . K"/MF OR "C21 H24 N4 O2 S . NA"/MF OR "C21
 H24 N4 O2 S . X C2 H F3 O2"/MF OR "C21 H24 N4 O2 S . X C2
 H2 O4"/MF OR "C21 H24 N4 O2 S . X C4 H4 O4"/MF OR "C21 H24
 N4 O2 S . X CL H"/MF)
 L45 1 SEA ABB=ON PLU=ON L44 AND HYDROXY?
 L46 1 SEA ABB=ON PLU=ON 223673-61-8/CRN
 L47 1 SEA ABB=ON PLU=ON 223673-61-8/RN

FILE 'HCAPLUS' ENTERED AT 15:25:13 ON 09 APR 2007

L48 2 SEA ABB=ON PLU=ON L46
 L49 4 SEA ABB=ON PLU=ON L47
 L50 4 SEA ABB=ON PLU=ON L48 OR L49
 L51 1 SEA ABB=ON PLU=ON L50 NOT L19
 L52 1 SEA ABB=ON PLU=ON L51 OR L20
 L53 0 SEA ABB=ON PLU=ON L46/DP OR /49/D
 L54 0 L38 NOT L49